A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma.
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05594381 |
|
Recruitment Status :
Not yet recruiting
First Posted : October 26, 2022
Last Update Posted : October 26, 2022
|
Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Collaborators:
Innovent Biologics (Suzhou) Co. Ltd.
Nanjing Geneseeq Technology Inc.
Information provided by (Responsible Party):
The First Affiliated Hospital with Nanjing Medical University
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Not yet recruiting |
|---|---|
| Estimated Primary Completion Date : | September 2023 |
| Estimated Study Completion Date : | October 2025 |